Patent

Article

scientific image
Press Release No. 1 Berlin

Developing a CRISPR therapy for muscular dystrophy

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular dystrophy with the help of gene-editing. Preclinical research led by the Spuler Lab published in “Nature Communications” now paves the way for first-in-human clinical trials.
woman
Science

From research to application

The Max Delbrück Center proudly welcomes Dr. Nevine Shalaby as the new Head of the Innovation and Entrepreneurship Department. With a rich background in genetics and industry, she aims to drive research impact, foster spin-offs, and strengthen industry partnerships, aligned with the Strategy 2030.
Wissenschaftliches Bild
Press Release No. 22 Berlin

Sharpening the gene scissors together

The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from Nice have agreed to cooperate to further develop their gene-editing tools. The aim is to utilize synergies, accelerate research, and ultimately develop cell therapies for genetically determined diseases.
Bild aus dem Labor
Science

Research collaboration to improve immunotherapies

The Berlin biotech Glycotope and the Max Delbrück Center have signed an agreement to explore the potential of combining Glycotope’s tumor-specific antibodies with CAR technology developed by the Max Delbrück Center. Their common goal: advancing immunotherapies against solid tumors.
Vier Personen
Science

Supporting innovation in biomedicine

The Max Delbrück Center wants to shape the future of medicine through innovation. But turning basic research into marketable products requires gaps to be bridged. This is achieved by the Technology Transfer Office – through funding schemes such as BOOST and Pre-GoBio. The winning projects for 2023 have now been selected.
Landthaler Akalin Lewin Header
Science

Long awaited by the pharma industry

It takes great patience and perseverance to turn research findings into new technologies or therapies. The Helmholtz Initiative and Networking Fund gives financial support to “pathfinder projects” that are particularly promising. Researchers at the Max Delbrück Center have now won grants for three projects.
T-cells (highlighted red) attacking a cancer cell
Press Release No. 1 Berlin

PlasmidFactory partnership to continue

Harnessing jumping genes to advance gene-therapy cancer treatment: In an effort to optimize the Sleeping Beauty system, the MDCell – Helmholtz Innovation Lab is extending its collaboration with PlasmidFactory.
Institute & Campus

The Product-Hatchers 

Transferring MDC inventions into pharmaceuticals and therapies – this is the mission driving MDC’s department of technology transfer. Their latest achievement, a pharmaceutical substance for atrial fibrillation developed by MDC spin-off OMEICOS Therapeutics, is now entering clinical trials.
Stock Photo newspapers
Science

Antibody against bone marrow tumor developed at MDC is put into application

Researchers at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) have developed antibodies against the cell surface protein BCMA that promise to heal multiple myeloma, a type of bone tumor that is at present incurable. The biotechnology company Heidelberg Pharma will now develop one of these antibodies to an antibody-toxin agent and test it clinically at the end of 2018. MDC and Heidelberg Pharma signed the underlying license agreement in January of 2017.
Press Release No. 35 Berlin

Technology transfer success: US approval for bleeding disorder drug

VONVENDI [von Willebrand factor (Recombinant)]”, the new drug from Baxalta Incorporated, a global biopharmaceutical company recently spun off from Baxter International, has just been approved by the United States Food and Drug Administration. It is the first, and so far the only, recombinant protein for the treatment of von Willebrand disease, and offers those affected a new therapeutic option for the first time in more than 10 years.